Kornimate/medical-research-clean huggingface dataset:
assessment of mesiodistal root angulation without radiographic guidance versus cbct guidance: a cross sectional study.

Conditions: Mesiodistal Root Angulation - Radiographic Guidance - CBCT Guidance - Assessment

Summary: digital transformation in the orthodontic field profoundly alters the way in which orthodontic treatment is perceived and delivered, moreover it aids in creating individualized orthodontic appliances.a crucial step in digital orthodontic planning in either indirect bonding or aligner treatment is localization of mesiodistal tip. earlier, panoramic radiographs were formerly recommended to assist clinicians in properly identifying mesiodistal root angulation. recommended to help clinician to identify mesiodistal root angulation accurately. owens et al. recorded clinically significant variation between the radiographic and the true root angulation. alternatively cbct (cone beam computed tomography) guided mesiodistal root angulation assessment has superior clinical significance compared to the routinely taken panoramic radiograph . despite its accuracy ,cbct is not justified as a part of diagnostic records for orthodontic treatment planning following the alara rule . to eliminate additional x ray dose computer aided mesiodistal root angulation identification is provided by several softwares such as orthoanalyzer™ ,orthocad® ,and suresmile® , however, the accuracy remains questionable. these finding may point out the importance of studying the accuracy mesiodistal identification to carry on digital workflow without the radiographic guidance.


Eligibility criteria:
inclusion criteria: * patients with digital models and panoramic radiograph as a routine diagnostic orthodontic record before treatment. * justified cbct record taken for impacted and ectopic teeth, planning for marpe (mini-screw assisted rapid palatal expansion)/mse (maxillary skeletal expansion), critical tooth movements in periodontally compromised patients, surgery first cases, taken for previous studies and other reasons. exclusion criteria: * severe crowding. * teeth with bizarre anatomy or severely decayed. * patients in mixed dentition stage.
thromboelastometry-guided treatment protocol versus standard care of major haemorrhage in obstetric patients

Conditions: Obstetric Labor Complications; Hemorrhage

Summary: this is a prospective, randomized and controlled study to find out if a rotational thromboelastometry(rotem) guided treatment protocol reduces the need for blood transfusions in major obstetric haemorrhage compared to standard care of clinical decision making, conventional coagulation tests and massive transfusion protocol. secondary aim is to find out if rotem can predict the incidence of thromboembolic events in this patient group.

a comparison of two different treatment protocols is made in patients suffering major obstetric haemorrhage: those who after a normal delivery are bleeding more than 1000 ml and are in need of surgical intervention to control the bleeding and those in cesarean section with ongoing bleeding of more than 1000 ml. patients are randomized in to two groups: the control group(n=30) will be treated according to a protocol based on clinical decision making, standard coagulation tests and massive transfusion packages of blood products(1:1:1), if needed. this is referred as 'standard care' in this hospital. the intervention group(n=30) will be treated according to a rotational thromboelastometry guided protocol, and massive transfusion packages, if needed. the study is powered to detect a reduction of one unit in red blood cell transfusion. blood product, fibrinogen concentrate, prothrombin complex concentrate usage and total amount of blood loss will be compared, and the number of transfusion related side effects and thromboembolic events 30 days after the bleeding will be recorded.

Eligibility criteria:
inclusion criteria: * age over 18 * severe post-partum haemorrhage ie. active bleeding of more than 1000ml within 24 hours after vaginal delivery or cesarean section * informed consent (after randomization) exclusion criteria: * known hemophilia or von willebrand's disease * unacceptance of allogeneic blood products(jehovah's witnesses)

Keywords: thromboelastometry obstetric hemorrhage blood component transfusion
clinical validation of the role of microrna binding site mutations in cancer risk, prevention and treatment

Conditions: Cancer

Summary: the investigators will recruit and enroll individuals that may have the kras-variant or other microrna binding site mutations to join registry studies. the investigators will allow individuals to obtain their results through a physician at the completion of the studies. the investigators current focus is cancer and autoimmunity.

the investigators have identified germ-line microrna binding site mutations that predict an increased risk of cancer, endometriosis and associated infertility, and unique tumor biology and response to treatment. the goal of this protocol is to further determine the mechanisms of these mutations, such as the kras-variant, and their associations with human health, such as cancer. the investigators will collect saliva samples from individual patients who are eligible and choose to enroll in these studies, to test for the kras-variant and/or other mutations under study. with specific permission, the investigators will keep excess dna to further investigate and discover additional similar mutations. the investigators purpose is to have participants answer questionnaires about lifestyle factors in an ongoing manner, to understand the impact of different factors on cancer risk for patients with these mutations.

Eligibility criteria:
inclusion criteria: * personal or family history of cancer * personal history of endometriosis, or autoimmunity exclusion criteria: * younger than 18 * non-english speaking and unable to understand and sign the consent

Keywords: breast cancer cancer risk family breast and ovarian cancer genetic cancer risk cancer treatment familial multiple primary cancer risk autoimmunity endometriosis
evaluation of the prevalence of e. coli o serotypes in paediatric population with recurrent urinary tract infection

Conditions: Urinary Tract Infections

Summary: this is a multicentre, observational, epidemiological study in which infants within the first 3 months of life with uti and children aged ≥4 months with r-uti will be recruited from nephrology /emergency departments and primary care in european countries

this is an international, multicenter, observational, cross-sectional epidemiological study. study participants will undergo a screening phase and will be checked for study eligible and inclusion/exclusion criteria at study entry. no other visits will be conducted other than the first evaluation. the study will be conducted across up to 26 participating sites in europe, including nephrology departments, paediatric emergency departments and primary care centers. specifically, sites located more in western and eastern europe will be involved in the study. in total, 600 participants with ruti (uti) will be included in this study, with approximately 200 participants for each age group (from 0 months to \< 3 years of age; from ≥ 3 to \< 12 years of age, from ≥ 12 to \< 18 years of age).

Eligibility criteria:
inclusion criteria: * age between 0 weeks and 17 years * significant urine culture positive only for e. coli * for infants up to 3 months of age, a confirmed first uti episode as identified by urine culture obtained by a sterile method (as described above) and positive for e. coli only (no other pathogens) * for children ≥4 months to \< 18 years a confirmed ruti episode as identified by urine culture obtained by a sterile method (as described above) and positive for e. coli only (no other pathogens) * collection of urine culture with a sterile method (suprapubic aspiration, bladder catheterization, clean voided urine) * signed informed consent form (signed by participant's legally authorized representative for participants who have not attained the age of majority) * signed assent form when appropriate, as determined by participant's age and individual site and country standards exclusion criteria: * patients ≥18 years * children ≥ 4 months of age with a first uti episode * absence of microbiological confirmation of uti * uti caused by bacteria other than e. coli or polymicrobial culture * urine collected with a non-sterile method (urinary bag) * uti episode within 30 days of the end of antibiotic treatment for the previous uti episode * second urine positive for e. coli during the same episode * patients in the active phase of anticancer treatment

Keywords: urinary tract infections recurrent urinary tract infections infants adolescents escherichia coli
effects of novel game rehabilitation system on upper extremity function of patients with stroke

Conditions: Stroke

Summary: the purpose of this study is to determine whether novel upper extremity rehabilitation system for patients with stroke(e-glove system) are effective in the rehabilitation compared to conventional occupational therapy


Eligibility criteria:
inclusion criteria: * hemiplegic stroke patients * medical research council scale \>= 2 of finger or wrist flexor/extensor * medical research council scale \>= 2 of elbow pronation/supination exclusion criteria: * bilateral weakness of upper extremities * uncontrolled medical or surgical illness * predisposing psychological or neurological disorders * severe aphasia unable to communicate * severe cognitive impairment not to cooperate * severe pain impeding upper extremity rehabilitation

Keywords: stroke hand rehabilitation game
the effects of guided imagery on postoperative pain management

Conditions: Healthy; Nursing Caries

Summary: this study was conducted to determine the effects of guided imagery on postoperative pain management.

the sample of the study consisted of 60 patients (30 in the experiment and 30 in the control groups) undergoing lower extremity operations at the orthopedics clinics of the kahramanmaras necip fazil city hospital. the study was conducted between april and september 2018.

Eligibility criteria:
inclusion criteria: * adult patients at and over the age of 18 * patients who were able to speak turkish * patients who received spinal anesthesia exclusion criteria: * patients who had not previously used guided imagery * patients any disease that could cause pain outside the surgery

Keywords: patient postoperative pain visual analogue scale guided imagery
dapaglifozin to avoid acute kindey injury (aki) to chronic kidney disease (ckd) transition: daki-ckd study

Conditions: AKI - Acute Kidney Injury; Biomarkers; Transition to CKD; CKD

Summary: justification: studies in recent years have shown that suffering an episode of acute kidney injury (aki) is an independent risk factor for developing chronic kidney disease (ckd), which is associated with cardiovascular complications, increases medical care costs, and decreases survival. these aki to erc transition cases add to the growing number of ckd cases already being seen globally. it is for them that in recent years therapeutic strategies have been sought to reduce or stop this process of transition from aki to ckd. objective: to evaluate the efficacy and safety of the use of dapagliflozin plus standard medical treatment (tms), compared with only tms for 21 days, in hospitalized patients with a diagnosis of severe aki (kdigo 3) in reducing the incidence of ckd to 18 months of follow-up. design: randomized, single center, open study. 100 hospitalized patients with a diagnosis of aki kdigo 3, without previous ckd, will be randomized to receive 10 mg of dapagliflozin every 24 h for 21 days + tms or only tms. during their follow-up, baseline blood and urine samples will be taken and at 3, 6, 12 and 18 months. at 18 months, the development of ckd will be assessed using the kdigo clinical criteria and with the determination of urinary biomarkers (serpina a3, hsp72, kim 1 and ngal).

it is planned to randomize 100 patients, 50 for each arm of the study. the randomization will be 1: 1 based on an open access computer program. group 1: dapagliflozin 10 mg, will be administered orally or by nasogastric tube every 24 h for 21 days. group 2: standard of care strategy, patients will receive the usual treatment for their pathology according to the judgment of their treating physician and the institutional practices, without receiving any of the interventional drugs. eligibility: adults (aged \>18 years) with aki 3 diagnosis for less than 24 h (kdigo classification, creatinine level or urine output criteria), hospitalized in general admission floor and/or intensive care unit. aki diagnosis must be compatible with the diagnosis of acute tubular necrosis in a context of ischemic or toxic aggression.

Eligibility criteria:
inclusion criteria: * adults (aged \>18 years) with aki 3 diagnosis for less than 24 h (kdigo classification, creatinine level or urine output criteria), hospitalized in general admission floor and/or intensive care unit. aki diagnosis must be compatible with the diagnosis of acute tubular necrosis in a context of ischemic or toxic aggression. exclusion criteria: * ckd stage 3b (kdigo) or more, renal transplant, urinary tract obstruction, thrombotic microangiopathy, acute glomerulopathy, cardiac arrest without awakening, oncological diagnosis with a life expectancy of less than 5 years, use of norephinephrine \>0.30 mcg/kg/min for 6 h or more, use of two vasopressors, pao2/fio2 ratio \<150, type 1 dm, fasting for more than 48 h, previous inclusion in other study, pregnant or breastfeeding woman.

Keywords: aki biomarkers no recovery
study for the quantification in ecological conditions of sensorimotor and dysexecutive disorders in cerebral palsy patients

Conditions: Dysexecutive Syndrome

Summary: executive functions are defined as the mental functions necessary for an individual to adapt to a complex or new environment that requires freedom from automatic and routine behavior. deficits in executive functions are described under the term "dysexecutive syndrome", and call into question the quality of social and professional life as well as the autonomy of patients. the usual methods of identifying dysexecutive syndrome are based essentially on batteries of neuropsychological tests known as "paper and pencil". however, these tests may lack sensitivity, in that they assess the patient in a very structured setting, very different from real life conditions, which are full of distractions and choices to be made. evaluations on real tasks are more rarely used but have the advantage of observing the difficulties encountered by a patient in everyday life. two tests of this type have been set up in the neurology department of the hôpital d'instruction des armées percy, and are integrated into the routine care of patients with a dysexecutive syndrome. for this purpose, a room in the department has been set up as a studio in order to reproduce as much as possible an everyday life environment, in which executive functions, fine motor skills, neurovegetative functions, emotional state, posture, locomotor skills and visual information capture can be measured ecologically.


Eligibility criteria:
inclusion criteria: * patients with a dysexecutive syndrome or healthy subjects * over 18 years-old exclusion criteria: * patients * psychiatric pathology (except for post-traumatic stress disorder) * pregnant or breastfeeding woman * healthy subjects * neurologic or psychiatric pathology * pregnant or breastfeeding woman
a study to investigate efficacy and safety of kbl697 in patients with moderate plaque type psoriasis

Conditions: Psoriatic Plaque

Summary: the study is designed to investigate efficacy and safety of kbl697 in patients with moderate plaque type psoriasis. kbl697 has been developed as a potential new treatment for psoriatic plaque.


Eligibility criteria:
inclusion criteria: * male or female, aged 18 to 75 years (inclusive) * have a diagnosis of plaque type psoriasis for ≥ 6 months * must have chronic plaque type psoriasis of moderate severity * all subjects must agree and commit to the use of a reliable contraceptive regimen. exclusion criteria: * current diagnosis of forms of psoriasis other than chronic plaque type only * drug-induced psoriasis * other inflammatory skin disease that may confound the evaluation of plaque psoriasis * failed 2 or more systemic treatments for plaque psoriasis * medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to baseline visit

Keywords: microbiome kbl697 plaque psoriasis
cytoflavin in combination with reperfusion in stroke patients

Conditions: Acute Stroke

Summary: evaluation of the efficacy and safety of cytoflavin®, solution for intravenous administration, (ooo ntff polysan, russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment within the first 24 hours from the stroke onset, compared to treament with any other neuroprotective drug which may be used in routine clinical practice.


Eligibility criteria:
inclusion criteria: 1. signed informed consent; 2. men and women 18-85 y.o.; 3. a diagnosis of "cerebral infarction" has been established and treatment with cytoflavin® has already been prescribed, or other therapy has been prescribed that does not include cytoflavin®; 4. nihss score of at least 5 and less than 24; 5. reperfusion therapy performed on admission; 6. the size of the ischemic focus according to aspects score \>=6; 7. time from stroke onset to admission not exceeeding 6 hours; 8. start of therapy with cytoflavin® within 24 hours from the onset of stroke (main group); 9. patients who are able to follow the procedures of the observational study program and strictly follow the doctor's instructions regarding drug therapy. exclusion criteria: 1. individual intolerance or known hypersensitivity to succinic acid, inosine, nicotinamide, riboflavin, or auxiliary components of the drug cytoflavin®; 2. hemorrhagic stroke; 3. contraindications for ct scanning; 4. initial severe disability requiring assistance in everyday life before stroke; 5. previous stroke with a residual neurological deficit; 6. severe comorbidity with a life expectancy of less than 6 months; 7. clinical or laboratory signs of an infectious disease on admission (with the exception of strokes that occurred in covid-19 convalescents after the first 10 days of illness, and patients with asymptomatic sars-cov-2 infection detected during routine examination); 8. pregnancy or lactation

Keywords: acute stroke cerebral infarction neuroprotection
neurotoxicity in primary central nervous system lymphoma (pcnsl): an international observational study of cognition in long term survivors

Conditions: Primary Central Nervous System Lymphoma (PCNSL)

Summary: this research is being done to investigate cognition in long term survivors of primary central nervous system lymphoma (pcnsl). sometimes caregivers as well as patients who no longer have the disease report cognitive problems such as reduced memory or attentional dysfunction and decreased quality of life. unfortunately, little is known about what may contribute to this cognitive dysfunction in part because pcnsl is a rare disease and sensitive tests have not often been used in the research studies. this project is being conducted to help understand what factors, such as radiation, may contribute to cognitive dysfunction and better define the relationship between brain structure and thinking in people who have had pcnsl.

this is an international, multi-center project that will enroll as many as 118 subjects of which approximately 35 will be enrolled at oregon health \& science university (ohsu). neuropsychological testing will consist of a battery of paper and pencil tests that examine abilities such as memory, motor skills, attention and speed of information processing. questionnaires that assess quality of life will also be administered. these noninvasive tests are administered by a trained examiner or neuropsychologist and last about 30 minutes. subjects will also undergo an mri of the head which provides a picture of the brain's structure by placing an individual inside a powerful magnet. statistical analyses will examine the relationship between the neuropsychological test scores and magnetic resonance (mr) images as well as examine the contribution of factors such as radiation, age, surgery, chemotherapy etc. to cognition.

Eligibility criteria:
inclusion criteria: * radiological and histological diagnosis of pcnsl * age 18 years or older * survived 2 years or more following treatment * able to complete neuropsychological and neuroimaging parts of the study * signed a written informed consent in accordance with institutional guidelines exclusion criteria: * subject has experienced recurrent disease * subject has a contraindication for mri * subject has a contraindication for neuropsychological testing * subject has stage iv or v renal insufficiency

Keywords: neurotoxicity cognition in survivors diagnostic imaging
extension study to assess the safety and efficacy of pasireotide in participants with cushing's disease

Conditions: Cushing Disease

Summary: cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (acth) secreting pituitary adenoma. this study assessed the long-term safety and efficacy of pasireotide in participants with cushing's disease.


Eligibility criteria:
inclusion criteria: * participants who have completed the 15 days of pasireotide treatment in the csom230b2208 study and have achieved normalization of 24-hour urinary free cortisol. participants who did not achieve normalization of 24 -hour urinary free cortisol may be enrolled if in the opinion of the investigator the participant is getting significant clinical benefits from treatment with pasireotide . * the participant did not experience any unacceptable adverse events of tolerability issues during the original 15 day treatment. * female participants of childbearing potential who have not undergone clinically documented total hysterectomy and/or ovariectomy or tubal ligation must agree to use barrier contraception throughout the course of the extension study, and for one month after the study has ended. exclusion criteria: * participant who have developed poorly controlled diabetes mellitus as indicated by ketoacidosis or hemoglobin (hgb) a1c (hgba1c) \> 10 since starting \[study csom230b2208\]. * participant with persistent alanine aminotransferase (alt)/ aspartate transaminase (ast) or alkaline phosphatase levels more than 2.5x upper limit of normal (uln), serum creatinine \> 2.0 x uln, serum bilirubin \> 2 x uln. * participant with abnormal coagulation (prothrombin time (pt) and partial thromboplastin time (ptt) elevated by 30% above normal limits), white blood cells (wbc) \<3.0x1'000'000'000/l; hgb \<12.0g/dl for females, hgb \<13.0g/dl for males; plt \<100x1'000'000'000/l. other protocol-defined inclusion / exclusion criteria may apply.

Keywords: cushing's disease acth cortisol acth dependent cushing's disease